Abstract
We report efficacy and safety with extended follow-up, and exploratory biomarker analyses from the phase II CheckMate 275 trial to identify biomarkers of response to nivolumab in platinum-resistant metastatic or unresectable urothelial carcinoma (mUC). Patients received nivolumab 3 mg/kg once every 2 weeks until disease progression, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was objective response rate (ORR) per blinded independent review committee (BIRC; using RECIST v1.1) in all treated patients and by tumor PD-L1 expression. Key secondary endpoints were progression-free survival (PFS) per BIRC using RECIST v1.1 and overall survival (OS) in all patients and by PD-L1 expression. Exploratory endpoints included safety and biomarker analyses of tumor mutational burden (TMB), PD-L1, and previously identified mutational signatures. Of 270 treated patients, 139 had evaluable TMB. With 33.7 months' minimum follow-up, ORR per BIRC, median PFS, and median OS [95% confidence interval (CI)] in all treated patients were 20.7% (16.1-26.1), 1.9 months (1.9-2.3), and 8.6 months (6.1-11.3), respectively. No new safety signals were identified. Higher TMB was associated (P < 0.05) with improved ORR [OR (95% C...Continue Reading
References
Jul 16, 2013·Nature Genetics·Steven A RobertsDmitry A Gordenin
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Oct 31, 2014·Nucleic Acids Research·Simon A ForbesPeter J Campbell
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Mar 15, 2015·Science·Naiyer A RizviTimothy A Chan
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Oct 28, 2016·Nature Genetics·Candace D MiddlebrooksLudmila Prokunina-Olsson
Dec 3, 2016·Nucleic Acids Research·Simon A ForbesPeter J Campbell
Jan 31, 2017·The Lancet Oncology·Padmanee SharmaMatthew D Galsky
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Oct 17, 2017·Cell·Nadeem RiazTimothy A Chan
Dec 23, 2017·Lancet·Thomas PowlesAlain Ravaud
Apr 17, 2018·The New England Journal of Medicine·Matthew D HellmannLuis Paz-Ares
Oct 3, 2018·European Urology·Nick van DijkMichiel S van der Heijden
Jan 13, 2019·Cancer Immunology Research·Erik YuskoJeffrey Weber
Jan 16, 2019·Nature Genetics·Robert M SamsteinLuc G T Morris
Jan 22, 2019·Genes, Chromosomes & Cancer·Albrecht StenzingerManfred Dietel
Feb 13, 2019·Cancer Cell·Matthew D HellmannScott J Antonia
Feb 23, 2019·ESMO Open·Reinhard BüttnerFrédérique Penault-Llorca
Jun 22, 2019·Cancer Science·Hao ChenXue Li
Jan 22, 2020·European Urology·Andrea NecchiJeffrey S Ross
Mar 29, 2020·Journal for Immunotherapy of Cancer·Diana M MerinoUNKNOWN TMB Harmonization Consortium
Apr 10, 2020·JAMA Oncology·Naiyer A RizviUNKNOWN MYSTIC Investigators
Citations
Aug 28, 2020·Frontiers in Cell and Developmental Biology·Xue-Jiao HanXia-Wei Wei
Aug 3, 2020·Journal of Translational Medicine·Jiaping LiYanhong Deng
Oct 7, 2020·International Journal of Molecular Sciences·Olga Bednova, Jeffrey V Leyton
Aug 8, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Umang SwamiNeeraj Agarwal
Nov 4, 2020·Cancer Discovery·Dan ShaFrank A Sinicrope
Feb 12, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jaehyun KimYong-Hee Kim
Jan 26, 2021·Bioscience Reports·Jie YuJinLong Yu
Feb 20, 2021·Seminars in Cancer Biology·Ionut-Gabriel FuninganaJames D Brenton
Mar 8, 2021·The AAPS Journal·Julianne D Twomey, Baolin Zhang
Mar 13, 2021·Targeted Oncology·Enrique GrandeAndrea Necchi
Apr 6, 2021·Current Opinion in Oncology·Alexander Y Andreev-DrakhlinJianjun Gao
Apr 19, 2021·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yumiko SakaiMikio Oka
Apr 28, 2021·Expert Opinion on Pharmacotherapy·Ariana L SantopietroJoaquim Bellmunt
Apr 20, 2021·Frontiers in Oncology·Zaishang LiFangjian Zhou
May 8, 2021·Hematology/oncology Clinics of North America·Rosa NadalJoaquim Bellmunt
May 8, 2021·Hematology/oncology Clinics of North America·Guru P Sonpavde
May 20, 2021·Clinical Genitourinary Cancer·Gregory R PondGuru Sonpavde
May 26, 2021·Journal of Translational Medicine·Yimin LiJinyi Lang
Jul 17, 2021·Journal for Immunotherapy of Cancer·Matthew D GalskyAshish M Kamat
Apr 11, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Li WangMatthew D Galsky
Sep 1, 2021·PLoS Medicine·Pradeep S ChauhanAadel A Chaudhuri
Nov 13, 2021·Future Oncology·Luis MezaSumanta K Pal